PXS-5382A

PXS-5382A is an oral small molecule inhibitor of lysyl oxidase-like 2 (LOXL2), developed initially by Pharmaxis and later by Syntara Limited (formerly Pharmaxis) and Synairgen. The drug is designed to inhibit LOXL2, an enzyme involved in the cross-linking of collagen and elastin in the extracellular matrix—a process implicated in tissue fibrosis. By blocking LOXL2 activity, PXS-5382A aims to reduce fibrotic tissue formation and progression in diseases such as idiopathic pulmonary fibrosis (IPF), non-alcoholic steatohepatitis (NASH), renal fibrosis, and other fibrotic conditions. Phase 1 clinical trials demonstrated that PXS-5382A was well-tolerated with a favorable safety profile and achieved significant inhibition of LOXL2 activity over a 24-hour period[1][3][5]. Despite initial promise for multiple indications, development has been discontinued for some diseases.

Other names

PXS 5382APXS5382APXS-5382APXS-5382PXS5382PXS 5382